Newer Phosphodiesterase Inhibitors: Comparison with Established Agents

Urologic Clinics of North America

Volumn 38, Issue 2, 2011, Pages 155-163

  McNamara, Erin R ^a   Donatucci, Craig F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Erectile dysfunction; Oral therapy; Phosphodiesterase 5; Phosphodiesterase 5 inhibitors

Indexed keywords

ALCOHOL; AVANAFIL; CYCLIC GMP; LODENAFIL; MIRODENAFIL; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; SLX 2081; SLX 2101; TA 1790; TADALAFIL; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ABNORMAL VISION; BACKACHE; COLOR VISION DEFECT; CORPUS CAVERNOSUM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOOD; FOOD DRUG INTERACTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; ISCHEMIC OPTIC NEUROPATHY; LIPID DIET; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY; PENIS ERECTION; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW; RHINITIS; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

ADMINISTRATION, ORAL; ERECTILE DYSFUNCTION; HUMANS; MALE; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 79957503285     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.03.005     Document Type: Review

References (47)

1. Jardin A. Recommendations of the 1st international consultation on erectile dysfunction. Erectile dysfunction 2000, Health Publications Ltd, Plymouth (UK).
2. Wessells H., Joyce G.F., Wise M., et al. Erectile dysfunction. J Urol 2007, 177(5):1675-1681.
3. Rosen R.C., Hatzichristou D., Broderick G. Clinical evaluation and symptom scales: sexual dysfunction assessment in men. Sexual medicine: sexual dysfunctions in men and women 2004, Health Publications, Paris (France). T. Lue, R. Basson, R. Rosen (Eds.).
4. Lue T.F. Erectile dysfunction. N Engl J Med 2000, 342(24):1802-1813.
5. Montague D.K., Jarow J.P., Broderick G.A., et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 2005, 174(1):230-239.
6. Wespes E., Amar E., Hatzichristou D.G., et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006, 49(5):806-815.
7. Feldman H.A., Goldstien I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151(1):54-61.
8. Burnett A.L., Lowenstein C.J., Bredt D.S., et al. Nitric oxide: a physiologic mediator of penile erection. Science 1992, 257(5068):401-403.
9. Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002, 56(6):453-459.
10. Rajfer J., Aronson W.J., Bush P.J., et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992, 326(2):90-94.
11. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998, 338(20):1397-1404.
12. Padma-Nathan H., Stecher V.J., Sweeny M., et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003, 62(3):400-403.
13. Gupta M., Kovar A., Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005, 45(9):987-1003.
14. Nichols D.J., Muirhead G.J., Harness J.A. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002, 53(Suppl 1):5S-12S.
15. Hellstrom W.J., Gittelman M., Karlin G., et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002, 23(6):763-771.
16. Hellstrom W.J., Gittelman M., Karlin G., et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003, 61(4 Suppl 1):8-14.
17. Montorsi F., Padma-Nathan H., Buvat J., et al. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med 2004, 1(2):168-178.
18. Rajagopalan P., Mazzu A., Xia C., et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003, 43(3):260-267.
19. Porst H., Padma-Nathan H., Giuliano F., et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003, 62(1):121-125. [discussion: 125-6].
20. Brock G.B., McMahon C.G., Chen K.K., et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002, 168(4 Pt 1):1332-1336.
21. Lewis R.W., Sadovsky R., Eardley I., et al. The efficacy of tadalafil in clinical populations. J Sex Med 2005, 2(4):517-531.
22. Peterson C. Pharmacokinetics of avanafil, a new PDE5 inhibitor being developed for erectile dysfunction. J Sex Med 2006, 3(Suppl 3):253-254.
23. Limin M., Johnsen N., Hellstrom W.J. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2010, 19(11):1427-1437.
24. Jung J., Choi C., Cho S.H., et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther 2010, 32(6):1178-1187.
25. Kim B.H., Lim H.S., Chung J.Y., et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 2008, 65(6):848-854.
26. Ahn G.J., Chung H.K., Lee C.H., et al. Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl 2009, 11(4):435-442.
27. Lee C.H., Shin J.H., Ahn G.J., et al. Udenafil enhances the recovery of erectile function and ameliorates the pathophysiological consequences of cavernous nerve resection. J Sex Med 2010, 7(7):2564-2571.
28. Paick J.S., Kim S.W., Park Y.K., et al. The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. J Sex Med 2009, 6(11):3166-3176.
29. Glina S., Toscano I., Gomatzky C., et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 2009, 6(2):553-557.
30. Glina S., Fonseca G.N., Bertero E.B., et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010, 7(5):1928-1936.
31. Lee S.K., Kim Y., Kim T.K., et al. Determination of mirodenafil and sildenafil in the plasma and corpus cavernous of SD male rats. J Pharm Biomed Anal 2009, 49(2):513-518.
32. Choi Y.H., Lee Y.S., Bae S.H., et al. Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. Biopharm Drug Dispos 2009, 30(6):305-317.
33. Paick J.S., Ahn T.Y., Choi H.K., et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008, 5(11):2672-2680.
34. Hatzimouratidis K., Hatzichristou D.G. Looking to the future for erectile dysfunction therapies. Drugs 2008, 68(2):231-250.
35. Prince W. SLx-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Sex Med 2006, 3(Suppl 1):29-30.
36. Stief C., Porst H., Saenz De Tejada I., et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004, 58(3):230-239.
37. Klotz T., Mathers M., Klotz R., et al. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)?. Int J Impot Res 2005, 17(1):2-4.
38. Carson C.C. Phosphodiesterase type 5 inhibitors: state of the therapeutic class. Urol Clin North Am 2007, 34(4):507-515. vi.
39. Kaufman J., Dietrich J. Safety and efficacy of avanafil, a new PDE5 inhibitor for treating erectile dysfunction. J Urol 2006, 175(Suppl 4):299.
40. Nehra A. Hemodynamic effects of co-administration of avanafil and glyceryl trinitrate. J Sex Med 2006, 3(Suppl 3):209.
41. Paick J.S., Kim S.W., Yang D.Y., et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008, 5(4):946-953.
42. Prince W.T., Campbell A.S., Tong W. SLx-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Sex Med 2006, 3(Suppl 1):29-30.
43. Pomeranz H.D., Bhavsar A.R. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol 2005, 25(1):9-13.
44. Carter J.E. Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?. J Neurol Sci 2007, 262(1-2):89-97.
45. Padma-Nathan H., Eardly I., Kloner R.A., et al. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002, 60(2 Suppl 2):67-90.
46. Kloner R.A., Eardley I., Kloner R.A., et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006, 97(12):1778-1784.
47. Reffelmann T., Kieback A., Kloner R.A. The cardiovascular safety of tadalafil. Expert Opin Drug Saf 2008, 7(1):43-52.